Results of imatinib mesylate (STI571), a bcr-abl tyrosine kinase inhibitor, in Philadelphia chromosome-positive chronic myelogenous leukemia in blastic phase (Ph plus CML BP).

被引：0
|
作者：
Kantarjian, HM
Cortes, J
O'Brien, S
Giles, F
Albitar, M
Rios, MB
Shan, J
Faderl, S
Garcia-Manero, G
Issa, JP
Thomas, D
Capdeville, R
Talpaz, M
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Novartis, Summit, NJ USA
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4772
引用
收藏
页码：260B / 260B
页数：1
相关论文
共 50 条
  • [1] Imatinib mesylate (STI571) therapy of Philadelphia chromosome-positive chronic myeloid leukemia in early chronic phase (Ph plus CML early CP).
    Kantarjian, HM
    Cortes, J
    O'Brien, S
    Giles, F
    Thomas, D
    Garcia-Manero, G
    Faderl, S
    Rios, MB
    Shan, J
    Hayes, K
    Keating, MJ
    Freireich, EJ
    Talpaz, M
    [J]. BLOOD, 2001, 98 (11) : 137A - 137A
  • [2] Regression of the Philadelphia chromosome (bcr/abl)-positive myelo- and megakaryopoiesis after Imatinib (STI571) therapy in chronic myelogenous leukemia (CML)
    Thiele, J
    Kvasnicka, HM
    Varus, E
    Kriener, S
    Engels, K
    Staib, P
    Ollig, ES
    Griesshammer, M
    Waller, CF
    Pfeifer, H
    Schmitt-Gräff, A
    [J]. PATHOLOGE, 2004, 25 (06): : 428 - 435
  • [3] Results of imatinib mesylate (STI571) in Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase (Ph plus CML-CP) post interferon alpha (IFN) failure.
    Kantarjian, HM
    Cortes, J
    O'Brien, S
    Faderl, S
    Thomas, D
    Giles, F
    Garcia-Manero, G
    Albitar, M
    Andreeff, M
    Kornblau, SM
    Rios, MB
    Shan, J
    Beran, M
    Koller, CA
    Resta, D
    Capdeville, R
    Estey, EH
    Keating, MJ
    Freireich, EJ
    Talpaz, M
    [J]. BLOOD, 2001, 98 (11) : 260B - 260B
  • [4] Treatment of accelerated phase of Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML AP) with imatinib mesylate (STI571).
    Kantarjian, HM
    O'Brien, S
    Cortes, J
    Faderl, S
    Giles, F
    Thomas, D
    Garcia-Manero, G
    Albitar, M
    Rios, MB
    Shan, J
    Issa, JP
    Resta, D
    Capdeville, R
    Keating, MJ
    Freireich, EJ
    Talpaz, M
    [J]. BLOOD, 2001, 98 (11) : 141A - 141A
  • [5] Phase II study of STI571, a tyrosine kinase inhibitor, in patients (pts) with resistant or refractory Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML).
    Kantarjian, H
    Sawyers, C
    Hochhaus, A
    Guilhot, F
    Schiffer, C
    Resta, D
    Capdeville, R
    Druker, B
    [J]. BLOOD, 2000, 96 (11) : 470A - 470A
  • [6] Competitive quantitative polymerase chain reaction (CQPCR) studies in Philadelphia chromosome positive chronic phase chronic myelogenous leukemia (Ph plus CML CP) on imatinib mesylate (STI571) therapy.
    Kantarjian, HM
    Arlinghaus, RB
    Quackenbush, RC
    Guo, JQ
    Cortes, J
    Giles, F
    Garcia-Manero, G
    Thomas, D
    Faderl, S
    Ford, JM
    [J]. BLOOD, 2001, 98 (11) : 614A - 614A
  • [7] BCR-ABL REARRANGEMENTS IN CHILDREN WITH PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA
    AURER, I
    BUTTURINI, A
    GALE, RP
    [J]. BLOOD, 1991, 78 (09) : 2407 - 2410
  • [8] Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR-ABL tyrosine kinase, CGP 57148
    Dan, S
    Naito, M
    Tsuruo, T
    [J]. CELL DEATH AND DIFFERENTIATION, 1998, 5 (08): : 710 - 715
  • [9] Monitoring minimal residual disease by BCR-ABL Western and quantitative competitive RT PCR in Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML) on STI571 therapy.
    Quackenbush, RC
    Talpaz, M
    Guo, JQ
    Arlinghaus, RB
    Resta, D
    Capdeville, R
    Rios, MB
    Giles, FJ
    Kantarjian, HM
    [J]. BLOOD, 2000, 96 (11) : 736A - 736A
  • [10] Effects of the tyrosine kinase inhibitor Imatinib mesylate (STI571) on bone marrow features in patients with chronic myelogenous leukemia
    Thiele, J
    Kvasnicka, HM
    Schmitt-Graeff, A
    Kriener, S
    Engels, K
    Staib, P
    Griesshammer, M
    Waller, CF
    Ottmann, OG
    Hansmann, M
    [J]. HISTOLOGY AND HISTOPATHOLOGY, 2004, 19 (04) : 1277 - 1288
12345